Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 29/05/2024 am IST			5-day change	1st Jan Change
1.15 ^USD	+2.69%		-1.71%	-64.51%

21/05	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/04	Sector Update: Health Care Stocks Increase Late Afternoon	MT

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

April 11, 2023 at 02:21 am IST

Hepion Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 42.2 million compared to USD 32.72 million a year ago. Basic loss per share from continuing operations was USD 11.8 compared to USD 9.4 a year ago.

Latest news about Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	22/05	CI
Sector Update: Health Care Stocks Increase Late Afternoon	23/04	MT
Sector Update: Health Care	23/04	MT
Top Midday Decliners	22/04	MT
North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	22/04	DJ
Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial	20/04	MT
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	20/04	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	06/03	CI
Hepion Pharmaceuticals, Inc. Announces Board Changes	21/02	CI
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	08/02	CI
North American Morning Briefing : Futures Pause -2-	08/12	DJ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	07/12	CI
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	07/12	MT
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director	07/12	CI
Hepion Pharmaceuticals, Inc. Announces CEO Changes	07/12	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	14/11	CI
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	25/23/25	CI
Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding	03/23/03	CI
Hepion Pharmaceuticals, Inc. announced that it expects to receive $5.000004 million in funding	28/23/28	CI
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat	21/23/21	CI
Aurinia Pharmaceuticals Appoints Robert Foster as Part of Deal With Shareholder MKT Capital	21/23/21	MT
Hepion Pharmaceuticals Reports Novel Rencofilstat Action in Liver Cancer	19/23/19	MT
Hepion Says Research Study on Idiopathic Pulmonary Fibrosis Involving Drug Candidate Rencofilstat Showed Positive Results	14/23/14	MT

Chart Hepion Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.15

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEPION PHARMACEUTICALS, INC.	-64.51%	61.29L
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.80%	11TCr
BIONTECH SE	-10.84%	2.34TCr
ARGENX SE	-1.69%	2.21TCr
GENMAB A/S	-10.23%	1.83TCr
WUXI APPTEC CO., LTD.	-41.92%	1.66TCr
BEIGENE, LTD.	-15.11%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.62%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+17.53%	1.17TCr

Bio Therapeutic Drugs